

EphA10 bispecific antibody for solid tumours

The Problem

The ephrin receptor A10 (EphA10) is a receptor tyrosine pseudo-kinase overexpressed in triple-negative breast cancer (TNBC) and lung adenocarcinoma (LUAD).

Despite their therapeutic potential, there are currently no drugs specifically developed and approved that target any Ephrin receptor.

The Solution


First in class bi-specific antibody that engages EphA10 on tumour cells and modulates immune responses through binding to PD-L1 or CD3.

We have screened the human antibody library in WEHI's Centre for Biologic Therapy, a collaborative initiative with CSL, and identified 4 lead candidates recognising distinct EphA10 epitopes.

Our Program

- Progress: We have generated four mAb lead candidates selectively targeting the EphA10 ectodomain on distinct epitopes (3 are rapids internalised, and one is blocking).
- Next steps: Optimisation of engineered antibody variants with reduced liabilities for bi-specific development; obtain comprehensive functional data on lead candidates.

We are seeking **partnerships and investment** to progress our antibody program



Ephrin A10 receptor (grey and green) bound to ligand (blue), with binding location of four mAb lead candidates.

Our Team

Prof. Isabel Lucet, Kinase signalling and structural biology
Dr. Jenny Vo, Advanced antibody discovery
Prof. Marie-Liesse Asselin-Labat, Lung cancer immunology

Ewa Michalak, PhD, Business Development
michalak.e@wehi.edu.au